BioPhausia's new share issue fully subscribed

BioPhausia's new share issue fully subscribed The new issue of 4,410,400 shares was fully subscribed. The share price was SEK 13, with preferential rights for shareholders. The new issue generated gross proceeds of SEK 57 M for the company. Uppsala, April 16, 1998 Based on its contact network and know-how, primarily in connective- tissue biology, BioPhausia is developing products for licensing to well-established pharmaceutical companies with strong marketing organizations. The project portfolio includes RescueFlow®, a resuscitation solution (registration phase), Krillase® for the debridement of chronic woundss (clinical phase III), and preclinical projects in the tumor and trauma treatment areas. Please contact the President, Stellan Lind, for further information about BioPhausia. Tel. +46-18-34 99 00


Documents & Links